9-oxo-N-phenyl-9H-fluorene-1-carboxamide | 55999-90-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 9-oxo-N-phenyl-9H-fluorene-1-carboxamide
• 英文别名: 9-oxo-H-phenyl-9H-fluorene-1-carboxamide；9-Fluorenon-4-carbonsaeure-anilid；9-oxo-N-phenylfluorene-1-carboxamide
• CAS: 55999-90-1
• 化学式: C₂₀H₁₃NO₂
• mdl: MFCD00275875
• 分子量: 299.329
• InChiKey: NHFBPAZHXVDQMC-UHFFFAOYSA-N

物化性质

• 沸点：
  445.2±24.0 °C(Predicted)
• 密度：
  1.338±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  9-芴酮-1-羧酸 、 苯胺 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 0.08h， 以68%的产率得到9-oxo-N-phenyl-9H-fluorene-1-carboxamide
  参考文献：
  名称：

  Structure-based redesign of an edema toxin inhibitor

  摘要：

  Edema factor (EF) toxin of Bacillus anthracis (NIAID category A), and several other toxins from NIAID category B Biodefense target bacteria are adenylyl cyclases or adenylyl cyclase agonists that catalyze the conversion of ATP to 3',5'-cyclic adenosine monophosphate (cAMP). We previously identified compound 1 (3-[(9-oxo-9H-fluorene-1-carbonyl)-amino]-benzoic acid), that inhibits EF activity in cultured mammalian cells, and reduces diarrhea caused by enterotoxigenic Escherichia coli (ETEC) at an oral dosage of 15 mu g/mouse. Here, molecular docking was used to predict improvements in potency and solubility of new derivatives of compound 1 in inhibiting edema toxin (ET)-catalyzed stimulation of cyclic AMP production in murine monocyte-macrophage cells (RAW 264.7). Structure-activity relationship (SAR) analysis of the bioassay results for 22 compounds indicated positions important for activity. Several derivatives demonstrated superior pharmacological properties compared to our initial lead compound, and are promising candidates to treat anthrax infections and diarrheal diseases induced by toxin-producing bacteria. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.091

文献信息

• Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure–activity relationships of the carboxamide group
  作者：William Kemnitzer、Nilantha Sirisoma、Bao Nguyen、Songchun Jiang、Shailaja Kasibhatla、Candace Crogan-Grundy、Ben Tseng、John Drewe、Sui Xiong Cai

  DOI：10.1016/j.bmcl.2009.04.009

  日期：2009.6

  cancer, HCT116 human colon cancer, and SNU398 hepatocellular carcinoma cancer cells. It arrested HCT116 cells in G2/M followed by apoptosis as assayed by the flow cytometry. Structure–activity relationship (SAR) studies of the carboxamide group identified the lead compound N-(2-(1H-pyrazol-1-yl)phenyl)-9-oxo-9H-fluorene-1-carboxamide (6s). Compound 6s, with increased aqueous solubility, was found to retain

  N-（2-甲基苯基）-9-氧代-9 H-芴-1-羧酰胺（2a）通过我们的基于半胱天冬酶和基于细胞的高通量筛选测定被鉴定为新型凋亡诱导剂。发现化合物2a具有亚微摩尔效能，在T47D人乳腺癌，HCT116人结肠癌和SNU398肝细胞癌细胞中对胱天蛋白酶的诱导和生长抑制均具有活性。如通过流式细胞术测定的，其将HCT116细胞阻滞在G 2 / M中，随后凋亡。羧酰胺基团的结构-活性关系（SAR）研究确定了先导化合物N-（2-（1 H-吡唑-1-基）苯基）-9-氧代-9 H-芴-1-羧酰胺（6s）。发现具有增加的水溶性的化合物6s在半胱天冬酶激活测定和在T47D，HCT116和SNU398细胞中分别具有亚微摩尔EC 50和GI 50值的细胞生长抑制测定中保留了广泛的活性。
• Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase
  申请人：Schein Catherine H.

  公开号：US20090093519A1

  公开（公告）日：2009-04-09

  Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3′,5′-adenosine monophosphate. Specific compositions of the invention are also novel.

  本发明描述了用于治疗和/或预防肠道液体丢失的小分子及其衍生物。还公开了使用所述分子及其衍生物治疗和/或预防与3′，5′-腺苷酸单磷酸增加水平相关的疾病的方法。本发明的特定组合物也是新颖的。
• Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis
  申请人：Kemnitzer E. William

  公开号：US20080096848A1

  公开（公告）日：2008-04-24

  The present invention is directed to substituted N-aryl-9-oxo-9H-fluorene-1-carboxamides and analogs thereof, represented by the general Formula I: (I) wherein R 1 -R 8 , X and Ar are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及取代的N-芳基-9-氧代-9H-芴-1-羧酰胺及其类似物，由通式I表示：（I）其中R1-R8、X和Ar的定义如本文所述。本发明还涉及发现具有I式化合物的化合物是caspase的活化剂和凋亡诱导剂。因此，本发明的caspase活化剂和凋亡诱导剂可用于在发生异常细胞的无控制生长和扩散的各种临床情况下诱导细胞死亡。
• METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE
  申请人：Schein Catherine H.

  公开号：US20120010233A1

  公开（公告）日：2012-01-12

  Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3′,5′-adenosine monophosphate. Specific compositions of the invention are also novel.

  本发明涉及用于治疗和/或预防肠道液体流失的小分子及其衍生物。还公开了使用所述分子及其衍生物治疗和/或预防与3′，5′-腺苷酸单磷酸酯水平增加相关的疾病的方法。本发明的特定组合物也是新颖的。
• Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives
  申请人：Erion Mark D.

  公开号：US20090118223A1

  公开（公告）日：2009-05-07

  Novel 2′-C-methyl nucleoside 5′-monophosphate and 4′-C-methyl nucleoside 5′-monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described.